A Phase 2 Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

Full Title

Purpose

Researchers want to see how well enfortumab vedotin works in people with adenoid cystic carcinoma. This cancer most often starts in the salivary glands and certain other glands in the body. The people in this study have adenoid cystic cancer that came back or spread after treatment.

Enfortumab vedotin is already used to treat people with bladder cancer. It delivers chemotherapy directly to cancer cells. It attaches to the surface of cancer cells and releases anti-cancer medication inside the cells. Enfortumab vedotin is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have adenoid cystic cancer that came back or spread after treatment.
• Have completed prior anti-cancer medications at least 4 weeks before getting enfortumab vedotin and any radiation therapy at least 2 weeks before.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Alan Ho’s office at 646-541-7062.